**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 84715

**Manuscript Type:** REVIEW

**Shifting perspectives in liver diseases after kidney transplantation**

Kosuta I *et al*. Liver diseases after KT

Iva Kosuta, Ana Ostojic, Ana Vujaklija Brajkovic, Jaksa Babel, Bojana Simunov, Maja Sremac, Anna Mrzljak

**Iva Kosuta, Ana Vujaklija Brajkovic, Jaksa Babel,** Department of Intensive Care Medicine, University Hospital Centre Zagreb, Zagreb 10000, Croatia

**Ana Ostojic, Maja Sremac, Anna Mrzljak,** Department of Gastroenterology and Hepatology, Liver Transplant Center, University Hospital Centre Zagreb, Zagreb 10000, Croatia

**Anna Mrzljak, Ana Vujaklija Brajkovic,** School of Medicine, University of Zagreb, Zagreb 10000, Croatia

**Bojana Simunov,** Department of Nephrology, University Hospital Merkur, Zagreb 10000, Croatia

**Author contributions:** Kosuta I contributed with literature review, analysis, and interpretation of data and drafting of the initial manuscript; Ostojic A, Vujaklija Brajkovic A, Babel J, Simunov B and Sremac M collected the data and drafted the initial manuscript; Mrzljak A contributed to the conception and design of the manuscript, making a critical revision of the initial manuscript and by making final approval of the article; All the authors approved the final version of the manuscript.

**Supported by** the Croatian Science Foundation, Project: Emerging and Neglected Hepatotropic Viruses after Solid Organ and Hematopoietic Stem Cell Transplantation, No. IP-2020-02-7407 (to Mrzljak A).

**Corresponding author: Iva Kosuta, MD, PhD, Attending Doctor,** Department of Intensive Care Medicine, University Hospital Centre Zagreb, Kispaticeva 12, Zagreb 10000, Croatia. ivakosuta@gmail.com

**Received:** March 26, 2023

**Revised:** May 15, 2023

**Accepted:** June 6, 2023

**Published online:**

**Abstract**

Liver diseases after kidney transplantation range from mild biochemical abnormalities to severe hepatitis or cirrhosis. The causes are diverse and mainly associated with hepatotropic viruses, drug toxicity and metabolic disorders. Over the past decade, the aetiology of liver disease in kidney recipients has changed significantly. These relates to the use of direct-acting antiviral agents against hepatitis C virus, the increasing availability of vaccination against hepatitis B and a better understanding of drug-induced hepatotoxicity. In addition, the emergence of the severe acute respiratory syndrome coronavirus 2 pandemic has brought new challenges to kidney recipients. This review aims to provide healthcare professionals with a comprehensive understanding of recent advances in the management of liver complications in kidney recipients and to enable them to make informed decisions regarding the risks and impact of liver disease in this population.

**Key Words:** Kidney transplantation; Viral hepatitis; Non-alcoholic fatty liver disease; Drug-induced liver injury; COVID-19

Kosuta I, Ostojic A, Vujaklija Brajkovic A, Babel J, Simunov B, Sremac M, Mrzljak A. Shifting perspectives in liver diseases after kidney transplantation. *World J Hepatol* 2023; In press

**Core Tip:** Liver disease is a common complication after kidney transplantation and can present in a variety of forms, from asymptomatic biochemical abnormalities to fibrosis/cirrhosis/decompensation/malignancy. Early recognition and referral to a hepatologist are crucial for effective treatment, as they can otherwise lead to impaired quality of life and increased morbidity. Screening of kidney transplant recipients for liver disease, including viral disease, metabolic disorders and drug toxicity, should be prioritised by healthcare providers.

**INTRODUCTION**

The efficacy of kidney transplantation (KT) in the treatment of end-stage renal disease (ESRD) has been demonstrated by numerous studies, which have shown that KT is associated with significantly higher survival rates and better quality of life compared to dialysis. As such, KT is now considered the gold standard in the treatment of ESRD[1,2]. Prevalence of chronic kidney disease (CKD) is estimated at 13.4% (11.7%-15.1%) and is on the rise due to increasing rates of diabetes, arterial hypertension, obesity and ageing. This is reflected in the increasing rates of KT; 92532 KT performed in 2021, which is an estimated 40% increase from 2008[2,3]. Advances in organ procurement, surgical techniques, immunosuppression regimens targeting rejection, and prophylactic antibiotic therapies have enabled excellent short-term survival rates after KT, and long-term outcomes are steadily improving over time[4]. This has led to a prolongation of life expectancy of both the graft and the recipient, which is now appreciable well beyond the first year following transplantation[4]. Survival rates of KT recipients may be affected by allograft nephropathy and subsequent failure, as well as a variety of morbidities, including cardiovascular disease (CVD) and infections associated with immunosuppressive drugs[1]. In addition, the incidence of liver abnormalities after KT, which ranges from 20% to 50%, was recently demonstrated by Vieira *et al*[5] to have a significant impact on the survival and quality of life of these patients[5] .

Liver disease after KT occurs in a variety of forms ranging from asymptomatic biochemical abnormalities to severe hepatitis, cirrhosis or malignancy[6]. Causes are heterogeneous and mainly related to hepatotropic viruses, drug toxicity and metabolic disorders[6]. Genetic conditions, such as polycystic kidney disease, which lead to the need for KT are also associated with polycystic liver disease[6]. Significant advances in understanding and treating liver disease in kidney transplant recipients have been made in the last decade. The development of direct-acting antiviral drugs (DAAs) for the treatment of hepatitis C virus (HCV) infection has led to a marked improvement in the treatment of HCV-related liver disease. Hepatitis E has been identified as a causative agent of chronic hepatitis and cirrhosis following solid organ transplantation (SOT). In addition to these advances, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its impact on SOT has highlighted the need for further research in this field. The impact of coronavirus disease 2019 (COVID-19) on liver function in kidney transplant recipients is not yet fully understood, and the long-term consequences of the virus on liver health in this population are still the subject of ongoing investigation. In addition, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide and it is also taking its toll in transplant population due to changes in eating habits, sedentary lifestyle and unavoidable effect of life-long immunosuppression[7]. This review aims to provide healthcare professionals with a comprehensive understanding of recent advances in the management of liver complications in KT recipients, allowing them to make informed decisions about the risks and impact of liver disease in this population.

**NON-ALCOHOLIC FATTY LIVER DISEASE**

NAFLD is a complex and multifactorial metabolic disorder influenced by a variety of genetic, environmental and lifestyle factors. The pathogenesis of NAFLD is characterised by a cascade of events that result in the accumulation of fat in the liver (hepatic steatosis), which can trigger an inflammatory response that further contributes to liver damage and leads to more severe liver diseases such as cirrhosis and hepatocellular carcinoma (HCC). However, the mechanisms underlying this progression remain unclear and are currently the subject of intense research efforts. Recent studies have highlighted the importance of gut microbiota dysbiosis, oxidative stress and immune system dysfunction in the development and progression of NAFLD[8]. Dysbiosis in the gut microbiota, characterised by a decrease in beneficial bacteria and an increase in harmful bacteria, can lead to increased gut permeability, endotoxaemia and inflammation, contributing to the development of NAFLD. Oxidative stress, an imbalance between reactive oxygen species and antioxidant defences, can also promote the progression of NAFLD by damaging hepatocytes and increasing the release of pro-inflammatory cytokines. Immune dysfunction, characterised by an imbalance between pro-inflammatory and anti-inflammatory metabolic pathways, can lead to an accumulation of immune cells in the liver, thus promoting the progression of NAFLD. In addition, genetic factors have been identified as important contributors to the development and progression of NAFLD. Variants in genes involved in lipid metabolism, insulin resistance and inflammation have been linked to an increased risk of NAFLD[8]. However, the interactions between genetic and environmental factors are complex and not fully understood, and more research is needed to fully elucidate the role of genetics in NAFLD.

NAFLD is now considered the most frequent chronic liver disease worldwide, with an estimated 25%-30%of the general population affected, particularly due to the rising prevalence of insulin resistance, obesity and hypertension[7]. Because type 2 diabetes mellitus (T2DM), obesity and dyslipidaemia often coexist with NAFLD, it is considered a hepatic manifestation of the metabolic syndrome[9]. While some experts suggest replacing the term NAFLD with metabolic-associated liver disease (MAFLD) to emphasise the importance of metabolic dysfunction in development and progression of the disease, the term is not yet universally accepted, as it can occur in patients without metabolic disorders[10]. In KT recipients, the high disease burden of NAFLD carries an increased risk of graft dysfunction and patient mortality, making early detection and treatment essential to reducing its impact on transplant outcomes. The increasing prevalence of NAFLD worldwide has led to a growing need for effective diagnostic and therapeutic strategies. Non-invasive diagnostic tools such as imaging and serum biomarkers have been developed to assess the severity of NAFLD and monitor disease progression. Various pharmacological and lifestyle interventions have also been investigated for the treatment of NAFLD, including weight loss, exercise, insulin-sensitising agents and antioxidants[11]. However, the optimal treatment for NAFLD remains uncertain, and more research is needed to find effective treatments that can prevent or reverse disease progression.

***NAFLD and CKD***

Patients with NAFLD and/or CKD share the same risk factors, including visceral obesity, arterial hypertension, prediabetes or T2DM, systemic insulin resistance, dyslipidaemia and low-grade inflammatory states[12]. Recently, several studies have shown that NAFLD is significantly associated with an increased prevalence of CKD. For example, the prevalence of CKD in patients with NAFLD ranged from 20% to 55%, while the prevalence of CKD in patients without NAFLD was 5% to 30%[13]. In addition, several retrospective and prospective cohort studies have found that the association between NAFLD and an increased incidence of CKD persists after adjustment for age, sex, obesity, hypertension and T2DM[14,15].

***Impact of NAFLD on KT recipients***

CVD is the main cause of mortality and graft loss after KT[16]. A meta-analysis of 16 studies found that patients with NAFLD had a higher risk of fatal and non-fatal cardiovascular events than patients without NAFLD (OR 1.64, 1.26-2.13) and that patients with severe NAFLD had a higher risk of fatal and non-fatal cardiovascular events (OR 2.58, 1.78-3.75)[17]. In addition, traditional risk factors (T2DM, obesity, hypertension, dyslipidaemia) for CVD and NAFLD may be exacerbated by immunosuppressive drugs, including calcineurin inhibitor and steroids in renal recipients[18]. In 2017, Kemmer and Buggs[19] reported the presence of NAFLD on ultrasound in 22% of KT candidates. Grupper *et al*[20] conducted a study of 341 consecutive KT recipients and showed that 36.4% of kidney recipients had sonographic evidence of NAFLD before transplantation. In the same study, recipients with NAFLD had a higher prevalence of new-onset diabetes before transplantation, and NAFLD was independently associated with cardiovascular mortality after KT (HR 4.4), even after adjustment for known CVD risk factors. It is still unclear whether NAFLD is associated with renal graft dysfunction. Grupper *et al*[20] found no correlation between graft function and NAFLD. However, from the studies already mentioned, NAFLD is significantly associated with a higher incidence of CKD in non-transplanted patients. This means that NAFLD and reduced graft function may also be the case in KT recipients[20]. The results of the above studies emphasise the need to diagnose NAFLD in KT recipients and to undertake aggressive risk factor modification early. The treatment of NAFLD in KT recipients is particularly challenging due to the complex interplay of metabolic disorders, immunosuppression and other comorbidities. Immunosuppressants used to prevent allograft rejection may exacerbate the metabolic disorder and contribute to the development and progression of NAFLD. Therefore, individualised treatment strategies that take into account each patient's unique needs are critical to achieving optimal outcomes according to KT. In addition, physicians caring for patients before and after KT should refer patients to a hepatologist as soon as NAFLD is diagnosed.

**VIRAL DISEASES**

***Hepatitis B virus***

The natural course of hepatitis B virus (HBV) infection is a dynamic process that reflects the interaction between HBV replication and the host immune response[21]. In immunocompetent adults, HBV infection is usually acute and self-limiting with more than 90% of patients achieving hepatitis B surface antigen (HBsAg) seroconversion within 6 mo, indicating natural resolution of the infection; however, infection in infancy or childhood often leads to chronicity[21]. Today, an estimated 240 million people are affected by chronic HBV infection[21]. Patients with detectable HBV DNA, especially those over 30 years of age and with a family history of HCC and cirrhosis, are typically considered for antiviral therapyand require lifelong treatment after KT[22,23]. Although modern antivirals such as entecavir or tenofovir result in viral suppression in almost all patients, treatment is long-term, possibly lifelong, and minimises the possibility of seroconversion[24]. Therefore, in chronically infected patients without signs of hepatitis, liver fibrosis or cirrhosis, without extrahepatic manifestations of HBV and with low viral replication rates (as determined by HBsAg and HBV DNA), treatment is not usually recommended by professional society guidelines[22,23]. In immunosuppressive states, *e.g.* due to chemotherapy or after organ transplantation, patients with cleared or inactive HBV may experience an abrupt increase in viral replication, which is called HBV reactivation.

Symptoms of HBV reactivation can range from asymptomatic to severe acute hepatitis, progression to chronic inflammation and fibrosis or HCC, and even acute liver failure. Where HBV is endemic, reported HBV reactivation rates with immunosuppression are as high as 41.5% (resolved HBV) and 70% (chronic HBV infection)[25,26]. As HBV prevalence in KT recipients ranges from 2.2 to 20.9% it is crucial that healthcare professionals understand their patient’s status to determine appropriate monitoring or antiviral prophylaxis measures to prevent reactivation[27].

***The patient with resolved HBV infection (HBsAg-negative, anti-HBc IgG positive recipient)***

Up to 30% of KT candidates may have resolved HBV infection [defined as HBsAg-negative and hepatitis B core antibody (anti-HBc) -positive], and 1.4%-9.6% may experience HBV reactivation after KT[27]. The American Association for the Study of Liver Diseases guidelines recommend monitoring every three months for the first year (alanine transaminase and HBV DNA) and antiviral prophylaxis only as an alternative[24]. However, since the risk factors for HBV reactivation are not precisely known, it is not clear which patients should be treated and which should be monitored. In a study by Mei *et al*[28] 52 patients with resolved HBV infection were retrospectively analysed. Five (9.6%) cases of HBV reactivation occurred, and anti-HBcAg titre (*P* = 0.042) and age (*P* = 0.037) were identified as risk factors for HBV reactivation. Interestingly, ATG treatment, steroid pulse doses and low-dose rituximab were not associated with HBV reactivation[28]. Shaikh *et al*[27] found that only 3.4% of KT recipients who did not receive antiviral prophylaxis experienced HBV reactivation, and delayed graft function was identified as a significant risk factor. Still, there were no significant adverse graft-related outcomes among those who experienced reactivation[27].

***The patient with chronic HBV infection (HBsAg-positive recipient)***

Chronic HBV is defined by persistent HBsAg in serum for at least 6 mo. Although current guidelines recommend prophylactic treatment for HBsAg-positive patients if they require immunosuppressive therapy for transplantation, most evidence is based on patients undergoing chemotherapy[22,23]. A systematic review and meta-analysis by Thongprayoon *et al*[29] included a total of 87623 KT patients and found significant association between HBsAg-positive status and poor outcomes, including mortality (pooled OR = 2.48; 95%CI: 1.61-3.83) and allograft failure (pooled OR = 1.46; 95%CI: 1.08-1.96). There was also a significant negative correlation between study year and risk of allograft failure, suggesting a possible improvement in patient and graft survival in HBsAg-positive recipients over time[29]. A recent study by Mo *et al*[30] confirmed high rates of viral reactivation in a real-world study of HBsAg-positive KT recipients, with inappropriate antiviral agents (all other than lifelong prophylaxis) (HR = 7.34, 95%CI 1.51-35.69, *P* = 0.01) and high levels of HBV DNA (≥ 1000 IU/mL) pre-transplant being the main risk factors (HR = 4.39, 95%CI 1.08-17.81, *P* = 0.04). However, the study found no difference in patients' or graft outcomes between patients who experienced reactivation and those who did not[30].

***The kidney graft from donors with resolved HBV infection (HBsAg-negative, anti-HBc IgG positive donor)***

Donors with resolved HBV infection may alleviate organ shortage in KT. A study by Yamada *et al*[31] found a low risk of reactivation - 45 cases of KT from donors with resolved HBV infection to HBV-naive recipients were analysed, and one patient (2.2%) became seropositive for anti-HBc, and one patient (2.2%) had detectable HBV-DNA levels after transplantation. In the same study, the presence of covalently closed circular DNA in transplanted organs from donors with resolved HBV infection and the capability of HBV replication in kidney cell lines was demonstrated[31]. Accordingly, further research is needed to fully evaluate the safety and efficacy of this approach.

***Hepatitis C virus***

HCV infection is a global health problem affecting an estimated 71 million people worldwide[32]. The prevalence of HCV tends to be higher in patients with ESRD and in KT recipients than in the general population[33]. Although transplantation of HCV-infected patients offers a clear survival advantage over dialysis, HCV positivity has often been a barrier to KT in the past. Possible reasons for this include concerns about impaired survival of grafts and patients associated with certain HCV-related causes, such as increased rates of liver fibrosis and glomerulonephritis[34]. Highly effective, all-oral DAAs have revolutionised HCV treatment with cure rates of > 95%[35]. DAAs not only improve outcomes in HCV-positive KT patients, but also open new opportunities to increase scarce graft availability by safely transplanting HCV-positive organs into HCV-negative recipients[36]. The focus of interest today is the efficacy and safety of DAAs after KT and the challenges of using HCV-positive grafts in HCV-negative recipients.

***DAA therapy for KT recipients***

Sofosbuvir, a second-generation DAA approved in 2013, paved the way for efficient interferon/ribavirin-free treatment of HCV. Today, DAAs have proven their efficacy and safety both in clinical trials and in practice[37-39]. Chute *et al*[37] reported sustained viral response (SVR) rates of 97% in 418 of KT recipients, most of whom were treated with sofosbuvir-based therapies[37]. In the phase-3, open-label, single arm MAGELLAN-2 study, which evaluated a 12-wk course of the pangenotypic regimen of glecaprevir/pibrentasvir SVR was achieved in 98% of patients[38]. In addition to confirming the efficacy of the different DAA regimens used (23 patients, 100% SVR rate), Alkadi *et al*[40] found that there were no significant changes in renal function or calcineurin inhibitor levels during or after therapy[40]. In another study, DAAs were found to reduce HCV prevalence from 1.97% to 0.43% among recipients of KT when used over a five-year period[41]. Current DAA regimen guidelines for KT recipients are readily available through the American Association for the Study of Liver Diseases/Infectious Diseases Society of America (AASLD/IDSA) and the European Association for the Study of the Liver (EASL) guidelines[35,42].

***ESRD and advanced liver disease***

The prevalence and clinical-epidemiological profile of HCV infection in ESRD have changed over time. In particular, patients today tend to be older than in the past; more deceased donors are used for transplantation; there are fewer co-infections with HBV, but a higher percentage of cirrhotic patients are treated. Additionally, decompensation was found to be more frequent in recent years as well as patient survival rate being lower than before[32]. Since cirrhosis is an important predictor of poor survival after KT, it is advisable sess the stage of liver fibrosis in all KT candidates. In patients with established cirrhosis and portal hypertension in whom antiviral HCV treatment fails or is not an option, combined liver and KT must be considered[43].

***Utilisation of HCV-positive donors***

One of the most important advances in the last decade to increase transplantation rates has been the practise of KT from HCV-positive donors to HCV-negative patients (HCV D+/R-), followed by DAA therapy. After the pioneering studies THINKER and EXPANDER, which demonstrated good graft function and found little evidence of adverse outcomes after HCV D+/R- KT, this practice steadily increased in the United States[44,45]. United Network for Organ Sharing (UNOS) data showed and found increasing rates (0.3% to 6.9%) of HCV D+/R- from 1/1/2017 to 12/12/2020[46]. A growing number of real-world studies confirm the safety and efficacy of the HCV D+/R- approach and highlight its advantages, including shorter waiting times, access to younger donors with excellent allograft function, and similar survival compared to HCV D-/R- KT[46,47]. Substantial additional administrative work may be required outside of clinical trials for insurance approval of DAA therapy. A study by Edmonds *et al*[47] found that the median time from KT to the first dose of DAA was 45 d[47]. However, even delayed initiation of DAA treatment, with a median of 70 d after KT, had no negative impact on SVR rates or liver histology[48].

Understanding gaps and benefits/risks of HCV D+/R- KT may lead to greater acceptance. The majority of patients are willing to accept HCV-positive organs after being educated, citing shorter waiting time, DAA efficacy and faster return to higher functional status[49]. However, Nguyen *et al*[50] revealed disparities in HCV D+/R- KT access based on race/ethnicity, gender, and education level; minorities were 15%-60%, women over 20%, and those with elementary school degrees or less half as likely to receive a HCV nucleic acid amplification technique (NAT) positive kidney compared to those with bachelor's degrees. These findings underscore unequal distribution of breakthrough treatments, which can take years before recognition or reporting occurs[50]. In conclusion, use of HCV-positive kidney grafts for HCV-negative recipients followed by DAA therapy is a potential solution to organ shortage that can improve quality of life of ESRD patients.

***Hepatitis E virus***

The understanding of hepatitis E virus (HEV) has evolved over the past decade. Genotypes (gt) 1 and 2 are restricted to developing countries and cause large epidemics *via* the faecal-oral route, while gt 3 and 4 are endemic zoonoses in high-income countries. Although HEV usually causes an acute and mild form of hepatitis in imunocompetent hosts, it can lead to more severe and long-lasting infections in individuals who have undergone a SOT[51]. This has become an increasingly important issue because HEV is now considered one of the primary causes of acute viral hepatitis and cirrhosis in transplant recipients. Data on the seroprevalence of HEV in haemodialysis patients are inconsistent, ranging from 0 to 44%, possibly due to significant differences between the geographical regions studied[52].

In 2008, the first report of chronic hepatitis due to gt 3 and 4 was published in SOT[53]. Subsequent studies showed that organ recipients are at increased risk of HEV infection, with prevalence ranging from 0.44% to 24% depending on the organ transplanted and the geographic region[54]. Interestingly, HEV seropositivity was significantly higher in transplant recipients compared to patients on the waiting list (24% *vs* 16.4%, *P* = 0.042)[55]. Still, it is possible that HEV infection is underdiagnosed in SOT recipients, as serological assays with low sensitivity are often used[56]. Clinical course is inconspicuous in most cases with mild but often persistent abnormalities observed in liver function tests[53]. To properly diagnose chronic HEV infection, serum or plasma samples and, if possible, stool samples must be examined using NATs[51]. High clinical suspicion of chronic HEV is important because undetected infection, especially with gt 3, can lead to rapid progression of liver fibrosis and in some cases decompensation and death[57].

KT recipients are particularly susceptible to chronic HEV infections, which can lead to serious complications such as earlier graft rejection. KT recipients with positive ELISA tests or PCR results for HEV are more likely than controls to experience earlier rejection[58]. It is known that HEV infection can cause hepatic and extrahepatic symptoms. A case study of a KT recipient with HEV and membranous nephropathy (MN) illustrates the possible causal relationship between the two conditions. Treatment with ribavirin (RV) as monotherapy proved effective in treating HEV infection and resulted in complete remission of the nephrotic syndrome. This suggests that RV may also have beneficial effects on MN *via* non-specific immunomodulatory mechanisms[59].

Although chronic HEV was originally defined as viral replication lasting longer than 6 mo, in an observational study of SOT recipients, clearance did not occur 3-6 mo after infection, but only within the first 3 mo. These results suggest that SOT patients who are viraemic for longer than 3 mo should be considered for treatment[60]. A recent study that investigated the efficacy of dose reduction of mycophenolic acid in eight KT patients diagnosed with chronic HEV infection showed that only one patient achieved HEV clearance, while most patients required antiviral treatment with RV. The study provided the clinical evidence that reducing mycophenolic acid therapy alone is not sufficient to control viral replication in transplant patients. In addition, rituximab has been identified as a risk factor for chronic HEV that is complicated to treat[61].

Meta-analysis data show that RV is a safe and effective treatment for chronic HEV infection in SOT recipients. RV induces a sustained virological response in 76% of patients and represents a first-line therapy for this patient group[62]. However, it is important to note that the guidelines recommend monitoring HEV RNA for at least six months after completion of RV therapy, as reinfection or relapse can occur even if the virus has been eliminated by therapy. This is especially true for immunosuppressed transplant patients, including those with positive anti-HEV IgG.

Trials in China have shown the efficacy of recombinant HEV genotype 1 vaccine (Hecolin®, Xiamen Innovax Biotech). However, the vaccine is not available outside China and its efficacy against other genotypes is unknown. Further studies in developed countries are needed to assess its efficacy, durability of immune response and cost-effectiveness before it can be recommended[63]. For now, avoiding contaminated food/water and thorough cooking are the only preventive measures.

***COVID-19***

Since identified in December 2019, SARS-CoV-2 has infected more than 660 million people to date[64]. SARS-CoV-2 causes COVID -19, which typically presents as an upper respiratory tract infection but can lead to severe pneumonia with acute respiratory distress syndrome and multiorgan failure[65]. The virus infects target cells by binding the spike surface glycoprotein (S) to angiotensin-converting enzyme 2 (ACE2), which is mainly expressed in cells of the alveolar epithelium type II[66]. However, it was also found in the heart, ileum, kidney, bladder and liver, with cholangiocytes being the major ACE2-expressing cell population, with a 20-fold higher expression rate than in hepatocytes[67]. This could potentially make the liver susceptible to SARS-CoV-2 virus, but evidence for specific viral hepatotropism is limited.

Abnormalities in liver function tests have been observed in up to 78% of hospitalized COVID-19 patients, with some individuals developing acute liver injury (ALI) and reports of liver failure due to SARS-CoV-2 infection[68,69]. Given the significantly higher expression of ACE2 receptors on cholangiocytes, one might generally expect a cholestatic laboratory pattern to predominate in patients with COVID-19, but this is not the case. Therefore, it has been hypothesised that liver injury is not primarily due to direct virus-induced damage to hepatocytes, but rather to indirect causes such as hepatotoxic drugs, systemic inflammatory responses and respiratory distress syndrome-induced hypoxia[70]. Some cases of acute de novo autoimmune hepatitis have also been reported following COVID-19, suggesting possible immunogenicity due to molecular mimicry of SARS-CoV-2[71]. Cholangiopathy resembling secondary biliary cholangitis, a possible chronic complication of COVID-19, has also been reported in critically ill patients[72]. In addition, the presence of cirrhosis among patients infected with SARS-CoV-2 is associated with a higher risk of death[73]. Major hepatic histopathological findings in patients with COVID-19 are nonspecific and mainly consist of hepatic steatosis, congestion of hepatic sinuses, vascular thrombosis, and portal/periportal tract lymphocytic infiltrates[74].

***Kidney transplant recipients***

KT recipients are often older, have multiple comorbidities and require chronic immunosuppression, and as such represent a high risk group for more serious COVID-19 disease. Since the onset of the pandemic, a large amount of data on recipients of SOT and KT have been reported, mainly from case series, small cohorts and larger registries. However, large multicentre studies with appropriate control groups are lacking. So, it remains a challenge how to appropriately treat KT recipients with COVID-19 and to understand what factors influence the outcomes. Clinical presentation, including abnormalities in liver function tests, has been shown to be similar in SARS-CoV-2 infected KT patients and in the general population[75].

In a multicentre cohort study the incidence of hepatitis was 20.2% among KT recipients, who received some form of antiviral therapy for SARS-SoV-2[76]. As in immunocompetent patients, the liver disease in KT recipients is usually mild and transient, characterised mainly by elevated levels of AST and ALT[76]. AST abnormality is more pronounced in patients with a severe form of the disease, and higher AST values have been shown to be a marker of poor outcome[77,78]. Early results from national and international registries and multicentre studies found a variable mortality rate of 18% to 32% among KT recipients hospitalised for COVID-19[77,79].

One distinctive feature that must be considered when assessing the possible aetiology of liver damage in patients with COVID-19 is the possibility of drug-induced liver injury (DILI) associated with certain treatments. Data on adverse events are sparse and often cannot be attributed with certainty exclusively to drugs for COVID-19, as a variety of other medications such as antibiotics and antipyretics are widely used in the treatment of such patients. To date various medications have been tried in treatment of SARS-CoV-2 infection – glucocorticoids, antimalarials, immunomodulatory agents (JAK2 inhibitors, IL-6 and IL-1 inhibitors), monoclonal antibodies, antiviral drugs and all of them may theoretically exhibit hepatotoxicity[80,81]. Table 1 Lists the hepatic contraindications and risk of drug induced liver injury (DILI) for drugs approved for the treatment of SARS-CoV-2 infection in the European Union and the United States of America[80-82].

**DRUG-INDUCED LIVER INJURY**

DILI, defined as liver injury caused by various drugs, herbs or other xenobiotics, results in abnormalities in liver tests or liver dysfunction, where other causes can be reasonably excluded[83]. The incidence of DILI is increasing worldwide due to the development of new drugs in the West and herbal preparations in Asia[83]. The classes of drugs most commonly associated with DILI include antibiotics, anticonvulsants and psychotropic drugs[84]. Polypharmacy, a common occurrence in KT recipients, increases the risk of drug interactions that may contribute to a higher incidence of DILI[84].

The severity of DILI can be associated with the dose of the consumed substance, *e.g.*, acetaminophen overdose/poisoning. However, most medications cause DILI in a non-dose dependent way, *i.e.*, idiosyncratically. Recent research proposed a 3-step model of DILI in which direct cell stress, direct mitochondrial inhibition and/or specific immune reactions can lead to mitochondrial permeability transition. Various environmental (age-related changes of pharmacokinetics, induction/inhibition of CYP450 enzymes, impaired antioxidant defence, immunological sensitisation, pre-existing liver disease, concomitant infections (*e.g.* HBV, HCV), mitochondrial dysfunction) and genetic factors may influence each sequence of the proposed model. In KT recipients, there are few potential environmental risk factors, *e.g.* drug interactions (antibiotics, antifungal and antiviral prophylaxis, immunosuppressive therapy), immunological sensitisation, malnutrition, infections and mitochondrial dysfunction due to diabetes, as well as all possible genetic risk factors that make them more susceptible to developing DILI than the general population. Previous research reported the occurrence of suspected DILI in 23% of KT recipients with possible causality in 57% of cases, and the associated drugs were antimicrobials, immunosuppressants and diuretics[84].

Assessing causality of DILI remains a challenge due to the lack of reliable biomarkers for hepatotoxicity. Several scoring systems are available, but there are discrepancies between scales. The best agreement seems to be between the Roussel-Uclaf Causality Assessment Method (RUCAM) scale and the Digestive Disease Week-Japan (DDW-J) scale, which includes an *in vitro* drug lymphocyte stimulation test (DLST) and is based on the RUCAM scale. Newer methods such as bile acid metabolomics could be used to assess the severity of DILI[85].

Despite some advances in the diagnosis and prognosis of DILI, the mainstay of treatment is to assess the need for immediate discontinuation of the suspect drug. N-acetylcysteine is currently a worldwide accepted treatment for acetaminophen hepatotoxicity. Bicyclol is a substance that may attenuate ALI by several mechanisms, including induction of autophagy, inhibition of oxidative stress and inactivation of the NLRP3 inflammasome. The results of the research in China show a satisfactory safety profile of the substance with a potentially favourable clinical outcome[86,87].

**AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASES**

Autosomal dominant polycystic kidney disease (ADPKD) is a prevalent genetic disorder causing uninhibited cyst growth in the kidneys, liver, and pancreas. It is one of the top causes of ESRD with an estimated occurrence rate ranging from 1:400 to 1000 live births due to mutations in PKD1 and PKD2 genes[88]. In addition, patients may present with other abnormalities, such as cerebral aneurysms, cardiac valve malformations, colonic diverticulosis, hernias of the abdominal wall and inguinal region, and cysts of the seminal vesicles[88]. Given the frequency of the disease, patients with ADPKD make up a large percentage of KT recipients. In rare cases, patients with ADPKD are referred for simultaneous liver and KT due to an enlarged liver leading to early satiety, abdominal pain and cachexia. In the majority of cases, however, synthetic liver function remains intact, so that most patients receive only a KT. After transplantation, liver cysts may continue to grow but rarely cause problems. Nevertheless, cyst complications must be included in the differential diagnosis of both fever of unknown origin in KT recipients with ADPKD (due to cyst inflammation) and abdominal pain (*e.g.* rupture).

For patients with symptoms of liver enlargement that persist after KT, there are several treatment options: surgical resection, fenestration or sclerotherapy of cysts, or drug treatment[89,90]. Liver transplantation and combined liver/KT have been performed in patients with severe, symptomatic disease. Sirolimus appears to reduce the volume of the polycystic liver, possibly through an antiproliferative effect. Liver volume was significantly lower in seven KT patients receiving sirolimus-mycophenolate-prednisone than in nine recipients receiving tacrolimus-mycophenolate-prednisone[91].

Recently, tolvaptan, an antidiuretic antagonist, was approved as the first therapy for ADPKD after the TEMPO and TEMPO-R trials demonstrated significantly less eGFR loss compared to the placebo group[92]. It is expected that more and more patients with ADPKD will be treated with tolvaptan in the future. Tolvaptan is a V2R antagonist that blocks vasopressin signalling, which plays an important role in cyst growth in ADPKD due to the resulting intracellular increase in cyclic adenosine monophosphate[92]. The main adverse effect of tolvaptan is liver toxicity, requiring frequent monitoring, and polyuria is a logical consequence of V2R blockade. However, adherence to tolvaptan appears to be well-feasible in the majority of patients[93]. Additional ongoing studies will determine whether the benefits are long-term, whether they can be observed in patients with advanced kidney disease and whether they can be translated into quality of life and cost/effectiveness parameters[94]. Tolvaptan may also be considered for patients after KT according to preliminary reports, taking into account the possible adverse effects, including hepatotoxicity, hypernatremia and alteration of serum tolvaptan concentration when used concomitantly with cyclosporine[95].

Other, rare cystic diseases, such as Autosomal Recessive Polycystic Kidney Disease, Autosomal Dominant Tubulointerstitial Kidney Disease and Carolli disease should also be considered in KT recipients[96].

**OTHER LIVER DISEASES**

***Iron overload***

Iron overload is a common problem in ESRD patients and transplant recipients, often resulting from the use of iron supplements to treat anaemia, the use of iron-based phosphate binders, and disruption of iron utilization due to chronic inflammation associated with CKD. Anaemia, defined as a hemoglobin concentration < 130 g/L in men and < 120 g/L in women, is a frequent complication of CKD[97]. The prevalence is 50%-70% in ESRD patients before transplantation and decreases to 51% at 6 mo and 37% at 2 years after KT[98]. Erythropoietin deficiency and impaired iron homeostasis, including absolute and functional iron deficiency, are major contributors to CKD-associated anaemia. Standard therapies for the treatment of anemia include exogenous substitution of erythropoietin, iron supplementation, and blood transfusion. The availability of erythropoiesis-stimulating agents has reduced the need for blood products and the risk of blood-borne infections, iron overload, and allosensitization. Recently, inhibitors of the hypoxia-inducible factor prolyl hydroxylase (HIF-PHI) have emerged as a new therapeutic option for anaemia. HIF-PHIs mediate both the erythropoietin and iron metabolism pathways. HIF-PHIs stabilize hypoxia-inducible factor (HIF), which stimulates endogenous erythropoietin production and affect the transcription of several iron metabolism and transport genes, leading to a decrease in ferritin levels and hepcidin levels[99-102]. HIF-PHIs can reduce the need for iron supplements by mobilizing stored iron[101]. Several randomized control trials in CKD patients regardless of dialysis status of roxadustat, vadadustat, and daprodustat showed no inferiority compared to ESA therapy with a similar safety profile[99,102-105]. These promising results could have significant clinical relevance as iron supplementation could be reduced.

Adequate iron stores are necessary for normal functioning of ESA and maintenance of stable hemoglobin levels. However, iron overload can lead to accumulation of iron in various organs. Iron-related side effects, mostly mediated by the formation of reactive oxygen species, can affect the liver (secondary hemochromatosis, cirrhosis), the heart (heart failure and arrhythmias), and endocrine organs (hypogonadism, diabetes mellitus). Excess iron can aggravate inflammation and shift the immunoregulatory balance, negatively affecting the immune system.

Serum ferritin and serum transferrin saturation (TSAT) are commonly used tests for iron status in CKD patients, including transplant recipients. Hepcidin measurement is not clinically more useful or better than TSAT and ferritin. Serum ferritin levels are affected by inflammation as it acts as an acute phase reactant. Serum ferritin levels ≤ 30 µg/L indicate iron deficiency. However, the ferritin value at which the iron stores in the bone marrow are filled is controversial. Currently, the 2012 KDIGO guidelines recommend iron supplementation therapy based on the combination of TSAT (≤ 30%) and ferritin (≤ 500 µg/L)[106].

**CONCLUSION**

Liver disease is a frequent occurrence following KT, estimated to affect 20%-50% of cases, and has a substantial impact on the survival and quality of life of these patients. Symptoms vary from asymptomatic, transient elevations of liver enzymes to the development of fibrosis and chronic liver failure. In severe cases, liver failure can have an acute onset or, in the chronic form, progress to cirrhosis with clinical indications of decompensation, or even the development of malignant disease such as HCC. Vigilant monitoring of KT recipients is crucial for the early detection of liver disease, allowing for timely intervention and improved outcomes. The incidence of viral diseases such as HBV and HCV has declined due to the effectiveness of antiviral medications and HBV vaccination programs. Globally, the prevalence of metabolic diseases such as NAFLD is rising, especially in transplant patients who are vulnerable due to lifelong immunosuppressive therapy. HEV and, more recently, SARS-CoV-2 have also been implicated as potential causes of liver disease. Additionally, healthcare professionals should be aware of the possibility of DILI, as many immunosuppressive and adjunct drugs can cause liver damage. Patients should be monitored closely for signs of drug toxicity, and medications should be adjusted accordingly. Screening KT recipients for liver disease is a priority for healthcare professionals. Early diagnosis and referral to a hepatologist are critical for managing underlying liver problems, which can adversely impact quality of life and general health.

**REFERENCES**

1 **Marbun MBH**, Susalit E, Susilowati U, Andina T. Long-term outcomes and prognostic factors in kidney transplant recipients in Jakarta, Indonesia: a cohort study. *BMJ Open* 2022; **12**: e059631 [PMID: 35641009 DOI: 10.1136/bmjopen-2021-059631]

2 **Wang JH**, Hart A. Global Perspective on Kidney Transplantation: United States. *Kidney360* 2021; **2**: 1836-1839 [PMID: 35373000 DOI: 10.34067/KID.0002472021]

3 **Lv JC**, Zhang LX. Prevalence and Disease Burden of Chronic Kidney Disease. *Adv Exp Med Biol* 2019; **1165**: 3-15 [PMID: 31399958 DOI: 10.1007/978-981-13-8871-2\_1]

4 **Poggio ED**, Augustine JJ, Arrigain S, Brennan DC, Schold JD. Long-term kidney transplant graft survival-Making progress when most needed. *Am J Transplant* 2021; **21**: 2824-2832 [PMID: 33346917 DOI: 10.1111/ajt.16463]

5 **Vieira GA**, Amaral ACC, Carvalho Filho RJ, Souza ALDS, Medina-Pestana JO, Ferraz MLG. Hepatic alterations in kidney transplant recipients from the largest kidney transplant center in brazil. *Arq Gastroenterol* 2022; **59**: 65-70 [PMID: 35442339 DOI: 10.1590/S0004-2803.202200001-12]

6 **Gunderson A**, Said A. Liver disease in kidney transplant recipients. *Transplant Rev (Orlando)* 2015; **29**: 1-7 [PMID: 25306468 DOI: 10.1016/j.trre.2014.08.002]

7 **Younossi ZM**, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016; **64**: 73-84 [PMID: 26707365 DOI: 10.1002/hep.28431]

8 **Juanola O**, Martínez-López S, Francés R, Gómez-Hurtado I. Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. *Int J Environ Res Public Health* 2021; **18** [PMID: 34069012 DOI: 10.3390/ijerph18105227]

9 **Adams LA**, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. *Gut* 2017; **66**: 1138-1153 [PMID: 28314735 DOI: 10.1136/gutjnl-2017-313884]

10 **Francque SM**, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus JV, Zelber-Sagi S, Hallsworth K, Busetto L, Frühbeck G, Dicker D, Woodward E, Korenjak M, Willemse J, Koek GH, Vinker S, Ungan M, Mendive JM, Lionis C. Non-alcoholic fatty liver disease: A patient guideline. *JHEP Rep* 2021; **3**: 100322 [PMID: 34693236 DOI: 10.1016/j.jhepr.2021.100322]

11 **Ahmed IA**, Mikail MA, Mustafa MR, Ibrahim M, Othman R. Lifestyle interventions for non-alcoholic fatty liver disease. *Saudi J Biol Sci* 2019; **26**: 1519-1524 [PMID: 31762620 DOI: 10.1016/j.sjbs.2018.12.016]

12 **Byrne CD**, Targher G. NAFLD as a driver of chronic kidney disease. *J Hepatol* 2020; **72**: 785-801 [PMID: 32059982 DOI: 10.1016/j.jhep.2020.01.013]

13 **Targher G**, Chonchol MB, Byrne CD. CKD and nonalcoholic fatty liver disease. *Am J Kidney Dis* 2014; **64**: 638-652 [PMID: 25085644 DOI: 10.1053/j.ajkd.2014.05.019]

14 **Park H**, Dawwas GK, Liu X, Nguyen MH. Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study. *J Intern Med* 2019; **286**: 711-722 [PMID: 31359543 DOI: 10.1111/joim.12964]

15 **Wilechansky RM**, Pedley A, Massaro JM, Hoffmann U, Benjamin EJ, Long MT. Relations of liver fat with prevalent and incident chronic kidney disease in the Framingham Heart Study: A secondary analysis. *Liver Int* 2019; **39**: 1535-1544 [PMID: 31033142 DOI: 10.1111/liv.14125]

16 **Ojo AO**, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. *Kidney Int* 2000; **57**: 307-313 [PMID: 10620213 DOI: 10.1046/j.1523-1755.2000.00816.x]

17 **Targher G**, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. *J Hepatol* 2016; **65**: 589-600 [PMID: 27212244 DOI: 10.1016/j.jhep.2016.05.013]

18 **Kasiske BL**. Risk factors for accelerated atherosclerosis in renal transplant recipients. *Am J Med* 1988; **84**: 985-992 [PMID: 3287917 DOI: 10.1016/0002-9343(88)90302-6]

19 **Kemmer N**, Buggs J. NAFLD in Kidney Transplant Candidates. In: 2017 American Transplant Congress. 2017: May 1; Tampa, FL, United States. *Am J Transplant* 2017;**17** (suppl 3)

20 **Grupper A**, Rabinowich A, Ben Shabat I, Tzadok R, Schwartz D, Schwartz IF, Goykhman Y, Kliuk Ben-Bassat O, Baruch R, Shashar M, Cohen-Hagai K, Katchman H. Nonalcoholic Fatty Liver Disease before Kidney Transplantation Correlates with New Onset Diabetes and Poor Metabolic Outcomes. *Am J Nephrol* 2022; **53**: 636-645 [PMID: 36075195 DOI: 10.1159/000526118]

21 **Burns GS**, Thompson AJ. Viral hepatitis B: clinical and epidemiological characteristics. *Cold Spring Harb Perspect Med* 2014; **4**: a024935 [PMID: 25359547 DOI: 10.1101/cshperspect.a024935]

22 **European Association for the Study of the Liver**. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol* 2017; **67**: 370-398 [PMID: 28427875 DOI: 10.1016/j.jhep.2017.03.021]

23 **Terrault NA**, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology* 2018; **67**: 1560-1599 [PMID: 29405329 DOI: 10.1002/hep.29800]

24 **Suk-Fong Lok A**. Hepatitis B Treatment: What We Know Now and What Remains to Be Researched. *Hepatol Commun* 2019; **3**: 8-19 [PMID: 30619990 DOI: 10.1002/hep4.1281]

25 **Sarin SK**, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepatol Int* 2016; **10**: 1-98 [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4]

26 **Seto WK**, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, Gill H, Lam YF, Lie AK, Lai CL, Kwong YL, Yuen MF. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. *J Clin Oncol* 2014; **32**: 3736-3743 [PMID: 25287829 DOI: 10.1200/JCO.2014.56.7081]

27 **Shaikh SA**, Kahn J, Aksentijevic A, Kawewat-Ho P, Bixby A, Rendulic T, Park JM. A multicenter evaluation of hepatitis B reactivation with and without antiviral prophylaxis after kidney transplantation. *Transpl Infect Dis* 2022; **24**: e13751 [PMID: 34725887 DOI: 10.1111/tid.13751]

28 **Mei T**, Noguchi H, Hisadome Y, Kaku K, Nishiki T, Okabe Y, Nakamura M. Hepatitis B virus reactivation in kidney transplant patients with resolved hepatitis B virus infection: Risk factors and the safety and efficacy of preemptive therapy. *Transpl Infect Dis* 2020; **22**: e13234 [PMID: 31856328 DOI: 10.1111/tid.13234]

29 **Thongprayoon C**, Kaewput W, Sharma K, Wijarnpreecha K, Leeaphorn N, Ungprasert P, Sakhuja A, Cabeza Rivera FH, Cheungpasitporn W. Outcomes of kidney transplantation in patients with hepatitis B virus infection: A systematic review and meta-analysis. *World J Hepatol* 2018; **10**: 337-346 [PMID: 29527269 DOI: 10.4254/wjh.v10.i2.337]

30 **Mo H**, Min S, Han A, Jung IM, Ha J. Outcome after kidney transplantation in hepatitis B surface antigen-positive patients. *Sci Rep* 2021; **11**: 11744 [PMID: 34083686 DOI: 10.1038/s41598-021-91331-y]

31 **Yamada R**, Morikawa K, Hotta K, Iwami D, Tanabe T, Murai S, Shinohara N, Yoshida S, Hosoda S, Kubo A, Tokuchi Y, Kitagataya T, Kimura M, Yamamoto K, Nakai M, Sho T, Suda G, Natsuizaka M, Ogawa K, Sakamoto N. Incidence of post-transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection. *J Viral Hepat* 2022; **29**: 976-985 [PMID: 36031873 DOI: 10.1111/jvh.13740]

32 **Popping S**, El-Sayed M, Feld J, Hatzakis A, Hellard M, Lesi O, Ninburg M, Ward J, Boucher C. Report from the International Viral Hepatitis Elimination Meeting (IVHEM), 17-18 November 2017, Amsterdam, the Netherlands: gaps and challenges in the WHO 2030 hepatitis C elimination framework. *J Virus Erad* 2018; **4**: 193-195 [PMID: 30050685 DOI: 10.1016/S2055-6640(20)30264-8]

33 **Emori CT**, Uehara SNO, Carvalho-Filho RJ, Amaral AC, de Souza E Silva IS, Lanzoni VP, Moreira SR, Silva-Souza AL, Gama RA, Nunes EJS, Leopércio APS, Appel F, Silva AEB, Medina-Pestana JO, Ferraz MLG. Changing pattern of chronic hepatitis C in renal transplant patients over 20 years. *Eur J Gastroenterol Hepatol* 2019; **31**: 1141-1147 [PMID: 30964809 DOI: 10.1097/MEG.0000000000001404]

34 **Scott DR**, Wong JK, Spicer TS, Dent H, Mensah FK, McDonald S, Levy MT. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. *Transplantation* 2010; **90**: 1165-1171 [PMID: 20861806 DOI: 10.1097/TP.0b013e3181f92548]

35 **Ghany MG**, Morgan TR; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. *Hepatology* 2020; **71**: 686-721 [PMID: 31816111 DOI: 10.1002/hep.31060]

36 **Shetty A**, Ariyamuthu VK, Gungor AB, Tanriover B. Utilization of hepatitis C virus-positive donors in kidney transplantation. *Curr Opin Organ Transplant* 2023; **28**: 22-28 [PMID: 36227758 DOI: 10.1097/MOT.0000000000001031]

37 **Chute DF**, Chung RT, Sise ME. Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient. *Kidney Int* 2018; **93**: 560-567 [PMID: 29325996 DOI: 10.1016/j.kint.2017.10.024]

38 **Reau N**, Kwo PY, Rhee S, Brown RS Jr, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. *Hepatology* 2018; **68**: 1298-1307 [PMID: 29672891 DOI: 10.1002/hep.30046]

39 **Fabrizi F**, Alonso C, Palazzo A, Anders M, Reggiardo MV, Cheinquer H, Zuain MGV, Figueroa S, Mendizabal M, Silva M, Ridruejo E; Latin American Liver Research, Educational and Awareness Network (LALREAN). 'Real-life' experience with direct-acting antiviral agents for HCV after kidney transplant. *Ann Hepatol* 2021; **25**: 100337 [PMID: 33684523 DOI: 10.1016/j.aohep.2021.100337]

40 **Alkadi MM**, Abuhelaiqa EA, Elshirbeny MF, Hamdi AF, Fituri OM, Asim M, Alkaabi SR, Derbala MF, Jarman ME, Ashour AM, Nauman A, Al Maslamani YK, Butt AA, Al-Malki HA. Eradication of hepatitis C virus infection in kidney transplant recipients using direct-acting antiviral therapy: Qatar experience. *Immun Inflamm Dis* 2021; **9**: 246-254 [PMID: 33264509 DOI: 10.1002/iid3.386]

41 **Devresse A**, Delire B, Lazarus JV, Kabamba B, De Meyer M, Mourad M, Buemi A, Darius T, Cambier JF, Goffin E, Jadoul M, Kanaan N. Eliminating Hepatitis C Virus From a Prevalent Kidney Transplant Recipient Population: A Single-Center Study in Belgium in the Direct-Acting Antivirals Era. *Transplant Proc* 2020; **52**: 815-822 [PMID: 32143864 DOI: 10.1016/j.transproceed.2020.01.021]

42 **European Association for the Study of the Liver.** Clinical Practice Guidelines Panel: Chair; EASL Governing Board representative:; Panel members:. EASL recommendations on treatment of hepatitis C: Final update of the series. *J Hepatol* 2020; **73**: 1170-1218 [PMID: 32956768 DOI: 10.1016/j.jhep.2020.08.018]

43 **Van Wagner LB**, Baker T, Ahya SN, Norvell JP, Wang E, Levitsky J. Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation. *J Hepatol* 2009; **51**: 874-880 [PMID: 19643508 DOI: 10.1016/j.jhep.2009.05.025]

44 **Goldberg DS**, Abt PL, Blumberg EA, Van Deerlin VM, Levine M, Reddy KR, Bloom RD, Nazarian SM, Sawinski D, Porrett P, Naji A, Hasz R, Suplee L, Trofe-Clark J, Sicilia A, McCauley M, Farooqi M, Gentile C, Smith J, Reese PP. Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients. *N Engl J Med* 2017; **376**: 2394-2395 [PMID: 28459186 DOI: 10.1056/NEJMc1705221]

45 **Durand CM**, Bowring MG, Brown DM, Chattergoon MA, Massaccesi G, Bair N, Wesson R, Reyad A, Naqvi FF, Ostrander D, Sugarman J, Segev DL, Sulkowski M, Desai NM. Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. *Ann Intern Med* 2018; **168**: 533-540 [PMID: 29507971 DOI: 10.7326/M17-2871]

46 **Concepcion BP**, Binari LA, Schaefer H, Rega S, Feurer I, Shawar S, Naik R, Hickman L, Walker J, Kapp M, Birdwell KA, Langone A, Helderman JH, Ann Sarrell B, Kochar G, Dubray B, Smith K, O'Dell H, DeMers A, Shelton P, Perri R, Shaffer D, Forbes RC. Kidney Transplantation From Hepatitis C Viremic Deceased Donors to Aviremic Recipients in a Real-world Setting. *Transplant Direct* 2021; **7**: e761 [PMID: 34514116 DOI: 10.1097/TXD.0000000000001217]

47 **Edmonds C**, Carver A, DeClercq J, Choi L, Peter M, Schlendorf K, Perri R, Forbes RC, Concepcion BP. Access to hepatitis C direct-acting antiviral therapy in hepatitis C-positive donor to hepatitis C-negative recipient solid-organ transplantation in a real-world setting. *Am J Surg* 2022; **223**: 975-982 [PMID: 34548142 DOI: 10.1016/j.amjsurg.2021.09.005]

48 **Kothadia JP**, Bhalla A, Molnar MZ, Mohan R, Balaraman V, Talwar M, Helmick R, Eymard C, Clark I, Jain R, Faust TW, Vanatta JM, Eason JD, Nair SP. Liver Outcome in Renal Transplant Recipients Who Acquired Hepatitis C Infection From an Infected Graft: Study Based on Liver Biopsy Findings. *Transplant Direct* 2022; **8**: e1342 [PMID: 35651584 DOI: 10.1097/TXD.0000000000001342]

49 **Cohen S**, Cowan V, Rohan V, Pavlakis M, Curry MP, Adler JT, Safa K, Fleishman A, Shenkel J, Rodrigue JR. Willingness of Kidney and Liver Transplant Candidates to Receive HCV-Infected Organs. *J Surg Res* 2022; **278**: 342-349 [PMID: 35667277 DOI: 10.1016/j.jss.2022.05.003]

50 **Nguyen T**, Sise ME, Delgado C, Williams W, Reese P, Goldberg D. Race, Education, and Gender Disparities in Transplantation of Kidneys From Hepatitis C Viremic Donors. *Transplantation* 2021; **105**: 1850-1857 [PMID: 33141804 DOI: 10.1097/TP.0000000000003511]

51 **European Association for the Study of the Liver**. EASL Clinical Practice Guidelines on hepatitis E virus infection. *J Hepatol* 2018; **68**: 1256-1271 [PMID: 29609832 DOI: 10.1016/j.jhep.2018.03.005]

52 **Mrzljak A**, Dinjar-Kujundzic P, Knotek M, Kudumija B, Ilic M, Gulin M, Zibar L, Hrstic I, Jurekovic Z, Kolaric B, Jemersic L, Prpic J, Tomljenovic M, Vilibic-Cavlek T. Seroepidemiology of hepatitis E in patients on haemodialysis in Croatia. *Int Urol Nephrol* 2020; **52**: 371-378 [PMID: 31894559 DOI: 10.1007/s11255-019-02363-3]

53 **Kamar N**, Selves J, Mansuy JM, Ouezzani L, Péron JM, Guitard J, Cointault O, Esposito L, Abravanel F, Danjoux M, Durand D, Vinel JP, Izopet J, Rostaing L. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. *N Engl J Med* 2008; **358**: 811-817 [PMID: 18287603 DOI: 10.1056/NEJMoa0706992]

54 **Kamar N**, Garrouste C, Haagsma EB, Garrigue V, Pischke S, Chauvet C, Dumortier J, Cannesson A, Cassuto-Viguier E, Thervet E, Conti F, Lebray P, Dalton HR, Santella R, Kanaan N, Essig M, Mousson C, Radenne S, Roque-Afonso AM, Izopet J, Rostaing L. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. *Gastroenterology* 2011; **140**: 1481-1489 [PMID: 21354150 DOI: 10.1053/j.gastro.2011.02.050]

55 **Samala N**, Wang RY, Auh S, Balla AK, Dakhoul L, Alter HJ, Farci P, Ghabril M, Lucey MR, Rangnekar AS, Reddy KR, Ghany MG. Hepatitis E prevalence and infection in solid-organ transplant recipients in the United States. *J Viral Hepat* 2022; **29**: 1134-1142 [PMID: 36036116 DOI: 10.1111/jvh.13739]

56 **Hansrivijit P**, Trongtorsak A, Puthenpura MM, Boonpheng B, Thongprayoon C, Wijarnpreecha K, Choudhury A, Kaewput W, Mao SA, Mao MA, Jadlowiec CC, Cheungpasitporn W. Hepatitis E in solid organ transplant recipients: A systematic review and meta-analysis. *World J Gastroenterol* 2021; **27**: 1240-1254 [PMID: 33828397 DOI: 10.3748/wjg.v27.i12.1240]

57 **Kamar N**, Abravanel F, Selves J, Garrouste C, Esposito L, Lavayssière L, Cointault O, Ribes D, Cardeau I, Nogier MB, Mansuy JM, Muscari F, Peron JM, Izopet J, Rostaing L. Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. *Transplantation* 2010; **89**: 353-360 [PMID: 20145528 DOI: 10.1097/TP.0b013e3181c4096c]

58 **Wasuwanich P**, Sirisreetreerux P, Ingviya T, Kraus ES, Brennan DC, Sue PK, Jackson AM, Oshima K, Philosophe B, Montgomery RA, Karnsakul W. Hepatitis E virus infection and rejection in kidney transplant recipients. *Transpl Immunol* 2022; **70**: 101517 [PMID: 34923120 DOI: 10.1016/j.trim.2021.101517]

59 **Taton B**, Moreau K, Lepreux S, Bachelet T, Trimoulet P, De Ledinghen V, Pommereau A, Ronco P, Kamar N, Merville P, Couzi L. Hepatitis E virus infection as a new probable cause of de novo membranous nephropathy after kidney transplantation. *Transpl Infect Dis* 2013; **15**: E211-E215 [PMID: 24103101 DOI: 10.1111/tid.12143]

60 **Kamar N**, Rostaing L, Legrand-Abravanel F, Izopet J. How should hepatitis E virus infection be defined in organ-transplant recipients? *Am J Transplant* 2013; **13**: 1935-1936 [PMID: 23659713 DOI: 10.1111/ajt.12253]

61 **Affeldt P**, Di Cristanziano V, Grundmann F, Wirtz M, Kaiser R, Benzing T, Stippel D, Kann M, Kurschat C. Monitoring of hepatitis E virus RNA during treatment for chronic hepatitis E virus infection after renal transplantation. *Immun Inflamm Dis* 2021; **9**: 513-520 [PMID: 33559399 DOI: 10.1002/iid3.411]

62 **Gorris M**, van der Lecq BM, van Erpecum KJ, de Bruijne J. Treatment for chronic hepatitis E virus infection: A systematic review and meta-analysis. *J Viral Hepat* 2021; **28**: 454-463 [PMID: 33301609 DOI: 10.1111/jvh.13456]

63 **Zhang J**, Zhang XF, Huang SJ, Wu T, Hu YM, Wang ZZ, Wang H, Jiang HM, Wang YJ, Yan Q, Guo M, Liu XH, Li JX, Yang CL, Tang Q, Jiang RJ, Pan HR, Li YM, Shih JW, Ng MH, Zhu FC, Xia NS. Long-term efficacy of a hepatitis E vaccine. *N Engl J Med* 2015; **372**: 914-922 [PMID: 25738667 DOI: 10.1056/NEJMoa1406011]

64 **Wang C**, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. *Lancet* 2020; **395**: 470-473 [PMID: 31986257 DOI: 10.1016/S0140-6736(20)30185-9]

65 **Richardson S**, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* 2020; **323**: 2052-2059 [PMID: 32320003 DOI: 10.1001/jama.2020.6775]

66 **Walls AC**, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* 2020; **181**: 281-292.e6 [PMID: 32155444 DOI: 10.1016/j.cell.2020.02.058]

67 **Chai X,** Hu L, Zhang Y, Han W, Lu Z, Ke A, Zhou J, Shi G, Fang N, Fan J, Cai J. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. 2020 Preprint. Available from: bioRxiv: 931766 [DOI:10.1101/2020.02.03.931766]

68 **Sobotka LA**, Esteban J, Volk ML, Elmunzer BJ, Rockey DC; North American Alliance for the Study of Digestive Manifestation of COVID-19. Acute Liver Injury in Patients Hospitalized with COVID-19. *Dig Dis Sci* 2022; **67**: 4204-4214 [PMID: 34487314 DOI: 10.1007/s10620-021-07230-9]

69 **Harapan H**, Fajar JK, Supriono S, Soegiarto G, Wulandari L, Seratin F, Prayudi NG, Dewi DP, Monica Elsina MT, Atamou L, Wiranata S, Aprianto DP, Friska E, Sari Firdaus DF, Alaidin M, Wardhani FA, Husnah M, Hidayati NW, Hendriyanti Y, Wardani K, Evatta A, Manugan RA, Pradipto W, Rahmawati A, Tamara F, Mahendra AI, Nainu F, Santoso B, Irawan Primasatya CA, Tjionganata N, Budiman HA. The prevalence, predictors and outcomes of acute liver injury among patients with COVID-19: A systematic review and meta-analysis. *Rev Med Virol* 2022; **32**: e2304 [PMID: 34643006 DOI: 10.1002/rmv.2304]

70 **Li X**, Wang W, Yan S, Zhao W, Xiong H, Bao C, Chen J, Yue Y, Su Y, Zhang C. Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management. *Front Pharmacol* 2022; **13**: 1019487 [PMID: 36518661 DOI: 10.3389/fphar.2022.1019487]

71 **Durazo FA**, Kristbaum K, Miller J, Saeian K, Selim M, Hong JC. De Novo Autoimmune Hepatitis after COVID-19 Infection in an Unvaccinated Patient. *Case Rep Hepatol* 2022; 2022: e8409269 [PMID: 36590671 DOI: 10.1155/2022/8409269]

72 **Faruqui S**, Okoli FC, Olsen SK, Feldman DM, Kalia HS, Park JS, Stanca CM, Figueroa Diaz V, Yuan S, Dagher NN, Sarkar SA, Theise ND, Kim S, Shanbhogue K, Jacobson IM. Cholangiopathy After Severe COVID-19: Clinical Features and Prognostic Implications. Am J Gastroenterol 2021; **116**: 1414–1425 [PMID: 33993134 DOI: 10.14309/ajg.0000000000001264]

73 **Ge J**, Pletcher MJ, Lai JC; N3C Consortium. Outcomes of SARS-CoV-2 Infection in Patients With Chronic Liver Disease and Cirrhosis: A National COVID Cohort Collaborative Study. *Gastroenterology* 2021; **161**: 1487-1501.e5 [PMID: 34284037 DOI: 10.1053/j.gastro.2021.07.010]

74 **Mondello C**, Roccuzzo S, Malfa O, Sapienza D, Gualniera P, Ventura Spagnolo E, Di Nunno N, Salerno M, Pomara C, Asmundo A. Pathological Findings in COVID-19 as a Tool to Define SARS-CoV-2 Pathogenesis. A Systematic Review. *Front Pharmacol* 2021; **12**: 614586 [PMID: 33867981 DOI: 10.3389/fphar.2021.614586]

75 **Monfared A**, Akhondzadeh L, Mousazadeh M, Jafari A, Khosravi M, Lebadi M, Aghajanzadeh P, Haghdar-Saheli Y, Movassaghi A, Ramezanzadeh E, Shobeirian F, Kazemnezhad E, Esmaeili S. COVID-19 in renal transplant recipients and general population: a comparative study of clinical, laboratory, and radiological features, severity, and outcome. *Virol J* 2021; **18**: 243 [PMID: 34876176 DOI: 10.1186/s12985-021-01713-x]

76 **Favà A**, Cucchiari D, Montero N, Toapanta N, Centellas FJ, Vila-Santandreu A, Coloma A, Meneghini M, Manonelles A, Sellarés J, Torres I, Gelpi R, Lorenzo I, Ventura-Aguiar P, Cofan F, Torregrosa JV, Perelló M, Facundo C, Seron D, Oppenheimer F, Bestard O, Cruzado JM, Moreso F, Melilli E. Clinical characteristics and risk factors for severe COVID-19 in hospitalized kidney transplant recipients: A multicentric cohort study. *Am J Transplant* 2020; **20**: 3030-3041 [PMID: 32777153 DOI: 10.1111/ajt.16246]

77 **Cravedi P**, Mothi SS, Azzi Y, Haverly M, Farouk SS, Pérez-Sáez MJ, Redondo-Pachón MD, Murphy B, Florman S, Cyrino LG, Grafals M, Venkataraman S, Cheng XS, Wang AX, Zaza G, Ranghino A, Furian L, Manrique J, Maggiore U, Gandolfini I, Agrawal N, Patel H, Akalin E, Riella LV. COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium. *Am J Transplant* 2020; **20**: 3140-3148 [PMID: 32649791 DOI: 10.1111/ajt.16185]

78 **Duarsa GWK**, Sugianto R, Yusari IGAAA, Tirtayasa PMW, Situmorang GR, Rasyid N, Rodjani A, Daryanto B, Seputra KP, Satyagraha P. Predictor factor for worse outcomes in kidney transplant recipients infected with coronavirus disease 2019: A systematic review and meta-analysis. *Transpl Immunol* 2023; **76**: 101739 [PMID: 36414181 DOI: 10.1016/j.trim.2022.101739]

79 **Caillard S**, Anglicheau D, Matignon M, Durrbach A, Greze C, Frimat L, Thaunat O, Legris T, Moal V, Westeel PF, Kamar N, Gatault P, Snanoudj R, Sicard A, Bertrand D, Colosio C, Couzi L, Chemouny JM, Masset C, Blancho G, Bamoulid J, Duveau A, Bouvier N, Chavarot N, Grimbert P, Moulin B, Le Meur Y, Hazzan M; French SOT COVID Registry. An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. *Kidney Int* 2020; **98**: 1549-1558 [PMID: 32853631 DOI: 10.1016/j.kint.2020.08.005]

80 **Gabrielli M**, Franza L, Esperide A, Gasparrini I, Gasbarrini A, Franceschi F, On Behalf Of Gemelli Against Covid. Liver Injury in Patients Hospitalized for COVID-19: Possible Role of Therapy. *Vaccines (Basel)* 2022; **10** [PMID: 35214651 DOI: 10.3390/vaccines10020192]

81 **Karlafti E**, Paramythiotis D, Pantazi K, Georgakopoulou VE, Kaiafa G, Papalexis P, Protopapas AA, Ztriva E, Fyntanidou V, Savopoulos C. Drug-Induced Liver Injury in Hospitalized Patients during SARS-CoV-2 Infection. *Medicina (Kaunas)* 2022; **58** [PMID: 36557050 DOI: 10.3390/medicina58121848]

82 **Delgado A**, Stewart S, Urroz M, Rodríguez A, Borobia AM, Akatbach-Bousaid I, González-Muñoz M, Ramírez E. Characterisation of Drug-Induced Liver Injury in Patients with COVID-19 Detected by a Proactive Pharmacovigilance Program from Laboratory Signals. *J Clin Med* 2021; **10** [PMID: 34640458 DOI: 10.3390/jcm10194432]

83. **Suk KT**, Kim DJ. Drug-induced liver injury: present and future. Clin Mol Hepatol 2012; **18**: 249–257 [PMID: 23091804 DOI: 10.3350/cmh.2012.18.3.249]

84 **Berradia A**. Descriptive Study of Drug Induced Liver Injury in Kidney Transplant Patients. *Adv Pharmacoepidemiol Drug Saf* 2020; **9**: 234 [DOI:10.4172/2167-1052]

85 **Xie Z**, Zhang L, Chen E, Lu J, Xiao L, Liu Q, Zhu D, Zhang F, Xu X, Li L. Targeted Metabolomics Analysis of Bile Acids in Patients with Idiosyncratic Drug-Induced Liver Injury. *Metabolites* 2021; **11** [PMID: 34940610 DOI: 10.3390/metabo11120852]

86 **Naiqiong W**, Liansheng W, Zhanying H, Yuanlin G, Chenggang Z, Ying G, Qian D, Dongchen L, Yanjun Z, Jianjun L. A Multicenter and Randomized Controlled Trial of Bicyclol in the Treatment of Statin-Induced Liver Injury. *Med Sci Monit* 2017; **23**: 5760-5766 [PMID: 29200411 DOI: 10.12659/msm.904090]

87 **Wang Y**, Lai R, Zong P, Xu Q, Shang J, Zhang X, Zhong W, Tang J, Han X, Chen C, Mao Y. Bicyclol for the treatment of drug-induced liver injury: a propensity score matching analysis using a nationwide inpatient database. *J Int Med Res* 2021; **49**: 3000605211005945 [PMID: 33853430 DOI: 10.1177/03000605211005945]

88 **Grantham JJ**. Clinical practice. Autosomal dominant polycystic kidney disease. *N Engl J Med* 2008; **359**: 1477-1485 [PMID: 18832246 DOI: 10.1056/NEJMcp0804458]

89 **Itou C**, Koizumi J, Hashimoto T, Myojin K, Kagawa T, Mine T, Imai Y. Foam sclerotherapy for a symptomatic hepatic cyst: a preliminary report. *Cardiovasc Intervent Radiol* 2014; **37**: 800-804 [PMID: 24170168 DOI: 10.1007/s00270-013-0761-5]

90 **Chebib FT**, Harmon A, Irazabal Mira MV, Jung YS, Edwards ME, Hogan MC, Kamath PS, Torres VE, Nagorney DM. Outcomes and Durability of Hepatic Reduction after Combined Partial Hepatectomy and Cyst Fenestration for Massive Polycystic Liver Disease. *J Am Coll Surg* 2016; **223**: 118-126.e1 [PMID: 27016902 DOI: 10.1016/j.jamcollsurg.2015.12.051]

91 **Qian Q**, Du H, King BF, Kumar S, Dean PG, Cosio FG, Torres VE. Sirolimus reduces polycystic liver volume in ADPKD patients. *J Am Soc Nephrol* 2008; **19**: 631-638 [PMID: 18199797 DOI: 10.1681/ASN.2007050626]

92 **Torres VE**, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. *N Engl J Med* 2012; **367**: 2407-2418 [PMID: 23121377 DOI: 10.1056/NEJMoa1205511]

93 **Perrone RD**, Chapman AB, Oberdhan D, Czerwiec FS, Sergeyeva O, Ouyang J, Shoaf SE. The Nocturne Randomized Trial Comparing 2 Tolvaptan Formulations. *Kidney Int Rep* 2020; **5**: 801-812 [PMID: 32518862 DOI: 10.1016/j.ekir.2020.03.011]

94 **Sans-Atxer L**, Joly D. Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations. *Int J Nephrol Renovasc Dis* 2018; **11**: 41-51 [PMID: 29430193 DOI: 10.2147/IJNRD.S125942]

95 **Akabane M**, Ishii Y, Nakamura Y, Yokoyama T, Miki K. Usefulness of Tolvaptan for the Postoperative Control After Kidney Transplantation in a Patient With Cardiac Hypofunction: A Case Report. *Transplant Proc* 2021; **53**: 1288-1291 [PMID: 33865611 DOI: 10.1016/j.transproceed.2021.03.018]

96 **Eckardt KU**, Alper SL, Antignac C, Bleyer AJ, Chauveau D, Dahan K, Deltas C, Hosking A, Kmoch S, Rampoldi L, Wiesener M, Wolf MT, Devuyst O; Kidney Disease: Improving Global Outcomes. Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management--A KDIGO consensus report. *Kidney Int* 2015; **88**: 676-683 [PMID: 25738250 DOI: 10.1038/ki.2015.28]

97 **Locatelli F**, Nissenson AR, Barrett BJ, Walker RG, Wheeler DC, Eckardt KU, Lameire NH, Eknoyan G. Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2008; **74**: 1237-1240 [PMID: 18596731 DOI: 10.1038/ki.2008.299]

98 **Hanna RM**, Streja E, Kalantar-Zadeh K. Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin. *Adv Ther* 2021; **38**: 52-75 [PMID: 33123967 DOI: 10.1007/s12325-020-01524-6]

99 **Singh AK**, Carroll K, McMurray JJV, Solomon S, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Więcek A, Blackorby A, Cizman B, Cobitz AR, Davies R, DiMino TL, Kler L, Meadowcroft AM, Taft L, Perkovic V; ASCEND-ND Study Group. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. *N Engl J Med* 2021; **385**: 2313-2324 [PMID: 34739196 DOI: 10.1056/NEJMoa2113380]

100 **Chen N**, Hao C, Liu BC, Lin H, Wang C, Xing C, Liang X, Jiang G, Liu Z, Li X, Zuo L, Luo L, Wang J, Zhao MH, Liu Z, Cai GY, Hao L, Leong R, Wang C, Liu C, Neff T, Szczech L, Yu KP. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. *N Engl J Med* 2019; **381**: 1011-1022 [PMID: 31340116 DOI: 10.1056/NEJMoa1901713]

101 **Kaplan JM**, Sharma N, Dikdan S. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease. *Int J Mol Sci* 2018; **19** [PMID: 29382128 DOI: 10.3390/ijms19020389]

102 **Fishbane S**, El-Shahawy MA, Pecoits-Filho R, Van BP, Houser MT, Frison L, Little DJ, Guzman NJ, Pergola PE. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study. *J Am Soc Nephrol* 2021; **32**: 737-755 [PMID: 33568383 DOI: 10.1681/ASN.2020081150]

103 **Provenzano R**, Shutov E, Eremeeva L, Korneyeva S, Poole L, Saha G, Bradley C, Eyassu M, Besarab A, Leong R, Liu CS, Neff TB, Szczech L, Yu KP. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. *Nephrol Dial Transplant* 2021; **36**: 1717-1730 [PMID: 33629100 DOI: 10.1093/ndt/gfab051]

104 **Chertow GM**, Pergola PE, Farag YMK, Agarwal R, Arnold S, Bako G, Block GA, Burke S, Castillo FP, Jardine AG, Khawaja Z, Koury MJ, Lewis EF, Lin T, Luo W, Maroni BJ, Matsushita K, McCullough PA, Parfrey PS, Roy-Chaudhury P, Sarnak MJ, Sharma A, Spinowitz B, Tseng C, Tumlin J, Vargo DL, Walters KA, Winkelmayer WC, Wittes J, Eckardt KU; PRO2TECT Study Group. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. *N Engl J Med* 2021; **384**: 1589-1600 [PMID: 33913637 DOI: 10.1056/NEJMoa2035938]

105 **Eckardt KU**, Agarwal R, Aswad A, Awad A, Block GA, Bacci MR, Farag YMK, Fishbane S, Hubert H, Jardine A, Khawaja Z, Koury MJ, Maroni BJ, Matsushita K, McCullough PA, Lewis EF, Luo W, Parfrey PS, Pergola P, Sarnak MJ, Spinowitz B, Tumlin J, Vargo DL, Walters KA, Winkelmayer WC, Wittes J, Zwiech R, Chertow GM. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. *N Engl J Med* 2021; **384**: 1601-1612 [PMID: 33913638 DOI: 10.1056/NEJMoa2025956]

106 **McMurray J,** Parfrey P, Adamson JW, Aljama P, Berns JS, Bohlius J, Drüeke TB, Finkelstein FO, Fishbane S, Ganz T, MacDougall IC. Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. *Kidney Int Suppl* 2012: 279-335 [DOI: 10.1038/kisup.2012.37]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** International Liver Transplantation Society; European Society of Intensive Care Medicine; European Society for Organ Transplantation; United European Gastroenterology; European Association for the Study of the Liver; Croatian Society of Gastroenterology.

**Peer-review started:** March 26, 2023

**First decision:** April 28, 2023

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Croatia

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Ouyang S, China; Sun X, China; Wang XL, China **S-Editor:** Li L **L-Editor:** A **P-Editor:**

**Figure Legends**



**Figure 1 Progress achieved to date and high priority topics in four main types of liver diseases affecting patients after kidney transplantation.** NAFLD: Non-alcoholic fatty liver disease; CNIs: Calcineurin inhibitors; DAAs: Direct acting antivirals; HCV D+/R-: Hepatits C virus donor positive/recipient negative; COVID-19: Coronavirus disease 2019; HEV: Hepatitis E virus; DILI: Drug induced liver injury; V2R: Vasopresin receptor 2; KT: Kidney transplantation.

**Table 1 Hepatic contraindications and risk of drug-induced liver injury among SARS-CoV-2 treatment drugs**

|  |  |  |
| --- | --- | --- |
| **Drug** | **Liver Contraindication** | **Risk of DILI** |
| Systemic corticosteroids | Caution in liver failure | + |
| Remdesivir | ALT > 5 × ULN | ++ |
| Tocilizumab | ALT > 5 × ULN | ++ |
| Sarilumab | ALT > 1.5 × ULN | ++ |
| Anakinra | Efficacy and safety in patients with AST/ALT ≥ 1.5 × ULN not been evaluated. | + |
|  | Not recommended with severe hepatic impairment (Child-Pugh C) |  |
| Baricitinib | Not recommended with severe hepatic impairment (Child-Pugh C) | + |
| Tofacitinib | Not recommended with severe hepatic impairment (Child-Pugh C) | + |
| Nirmatrelvir/ritonavir | Not recommended with severe hepatic impairment (Child-Pugh C) | + |
| Lopinavir/ritonavir | Not recommended with severe hepatic impairment (Child-Pugh C) | ++ |
| Molnupiravir | Limited experience of the use with any degree of hepatic impairment. | + |
| Casirivimab/imdevimab | Not recommended with severe hepatic impairment (Child-Pugh C) | + |
| Sotrovimab | No data in patients with ALT 5 to < 10 × ULN). | + |
| Tixagevimab/cilgavimab | Not been evaluated in patients with hepatic impairment | + |
| Regdanvimab | Not been evaluated in patients with hepatic impairment | + |

ALT: Alanine transaminase; AST: Aspartate aminotransferase; ULN: Upper limit normal; +: Uncommon; ++: Common; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.